Appendix 4E, Directors Report and Financial Statements
Filed with ASX · · 70 pages · English
Watch Mayne Pharma's latest callMayne Pharma Group (ASX:MYX) Q4 2026 Earnings Call · Replay · Aug 26
Mayne Pharma Group Ltd. on 6ix
In the deck
Story so far
Earlier from Mayne Pharma
- MYX announces acquisition of US foam dermatology assets
- MYX announces settlement from patent infringement case
- Completion institutional entitlement offer and placement
- MYX announces acquisition of US generic product portfolio
- MYX receives first generic approval of Tikosyn capsules
Later from Mayne Pharma
- MYX launches generic Entocort EC (Budesonide) capsules
- IDT: 1st generic proprietary prod shipped to US, temozolomide
- MYX launches generic MS Contin (morphine sulfate) tablets
- S&P DJ Indices Announces March Quarterly Rebalance
- Update on Status of DOJ Investigation
Follow Mayne Pharma into a list and get an email when it puts out news.
Follow Mayne Pharma